Duffy antigen receptor for chemokines in laryngeal squamous cell carcinoma as a negative regulator

Duffy antigen receptor for chemokines (DARC), as a negative regulator, could attenuate the potential growth and metastasis of laryngeal squamous cell carcinoma (LSCC); hence it could be considered as a basis for a new prognostic aid and molecular therapeutic target in treating LSCC.

To analyze the role of DARC in LSCC progression using LSCC clinical samples.

A total of 65 LSCC tissues were examined immunohistochemically for DARC protein expression. The microvessel density (MVD) was determined by the endothelial cells immunostained using anti-CD34 antibody.

It was found that DARC was expressed in the LSCC samples, with a high expression in 32 of our cases (49.2%), and in lymph node-negative and -positive groups of 24 (72.7%) and 8 cases (25%), respectively (p < 0.01). MVD was (24.75 ± 5.45)/High power field (HP) and (32.58 ± 5.23)/HP in the cases with high and low expression of DARC, respectively (p < 0.01). More importantly, the DARC expression presented a strong negative correlation with nodal metastasis, with pTNM stage, and with recurrence, and the cases with a high DARC expression indicated a higher survival rate. In addition, the multivariate analysis showed that the DARC expression was an independent prognostic factor (p = 0.032; hazard ratio, 21.476; 95% confidence interval, 1.297-355.68).